» Articles » PMID: 38233247

Standards for the Care of People with Cystic Fibrosis (CF); Recognising and Addressing CF Health Issues

Abstract

This is the third in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on recognising and addressing CF health issues. The guidance was produced with wide stakeholder engagement, including people from the CF community, using an evidence-based framework. Authors contributed sections, and summary statements which were reviewed by a Delphi consultation. Monitoring and treating airway infection, inflammation and pulmonary exacerbations remains important, despite the widespread availability of CFTR modulators and their accompanying health improvements. Extrapulmonary CF-specific health issues persist, such as diabetes, liver disease, bone disease, stones and other renal issues, and intestinal obstruction. These health issues require multidisciplinary care with input from the relevant specialists. Cancer is more common in people with CF compared to the general population, and requires regular screening. The CF life journey requires mental and emotional adaptation to psychosocial and physical challenges, with support from the CF team and the CF psychologist. This is particularly important when life gets challenging, with disease progression requiring increased treatments, breathing support and potentially transplantation. Planning for end of life remains a necessary aspect of care and should be discussed openly, honestly, with sensitivity and compassion for the person with CF and their family. CF teams should proactively recognise and address CF-specific health issues, and support mental and emotional wellbeing while accompanying people with CF and their families on their life journey.

Citing Articles

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study.

Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G Ther Adv Respir Dis. 2025; 19:17534666251314706.

PMID: 39930791 PMC: 11811973. DOI: 10.1177/17534666251314706.


Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve.

Harrigan M, Georgiopoulos A, Quittner A, Smith B, Douglas T BMJ Open Respir Res. 2025; 12(1).

PMID: 39929550 PMC: 11815457. DOI: 10.1136/bmjresp-2024-002606.


An overview of proactive monitoring and management of respiratory issues in ataxia-telangiectasia in a specialist and shared care pediatric clinic.

Bhatt J, Bush A Front Pediatr. 2025; 12:1479620.

PMID: 39764161 PMC: 11701024. DOI: 10.3389/fped.2024.1479620.


Respiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.

Lanfranchi C, Alicandro G, Cariani L, Orena B, Gramegna A, Rizza C Lung. 2025; 203(1):24.

PMID: 39762638 DOI: 10.1007/s00408-024-00781-4.


A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?.

Poamaneagra S, Plesca D, Tataranu E, Marginean O, Nemtoi A, Mihai C J Clin Med. 2024; 13(23).

PMID: 39685886 PMC: 11642410. DOI: 10.3390/jcm13237428.